Literature DB >> 33682610

Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City.

Brandon Muncan1, Ashly E Jordan2,3,4, David C Perlman3,5, David Frank2,3, Danielle C Ompad3,6, Suzan M Walters2,3.   

Abstract

Introduction/
Objectives: The incidence of hepatitis C (HCV) infection is rising among people who inject drugs (PWID). Even in the context of known HCV prevention and treatment strategies, some PWID remain unengaged in HCV care. This study aimed to identify and characterize experiences and perceptions of PWID regarding the acceptability and effectiveness of HCV testing and treatment at a local syringe service program (SSP).
Methods: A total of 36 PWID participated in semi-structured interviews at an SSP in New York City. Interviews were audio-recorded, transcribed, and coded by three coders, following a constructivist grounded theory approach. Relevant themes were identified as they emerged from the data.
Results: Interviews with PWID revealed three themes related to the impact of SSPs on HCV care: (1) non-stigmatizing SSP environments, (2) the role of SSPs in improving HCV knowledge, and (3) acceptability of SSPs as sites for HCV care among PWID. Discussion: This paper contributes to the ongoing understanding that SSPs provide a well-accepted source of HCV services for PWID. Participants believed that SSPs are accessible and effective sites for HCV care, and suggested that stigma among PWID continues to affect receipt of HCV care in traditional settings. Conclusions: Understanding attitudes and beliefs of PWID regarding the effectiveness of SSPs as sites for HCV care is crucial for the development of focused strategies to reduce HCV transmission, and to ultimately achieve HCV elimination. Given this, further research is warranted investigating how best to improve HCV care at harm reduction sites such as SSPs.

Entities:  

Keywords:  Cluster; Hepatitis C; Syringe service programs; people who inject drugs; stigma

Mesh:

Substances:

Year:  2021        PMID: 33682610     DOI: 10.1080/10826084.2021.1892142

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  8 in total

1.  Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.

Authors:  Shelley N Facente; Rachel Grinstein; Roberta Bruhn; Zhanna Kaidarova; Erin Wilson; Jennifer Hecht; Katie Burk; Eduard Grebe; Meghan D Morris
Journal:  PLoS One       Date:  2022-05-11       Impact factor: 3.752

2.  Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.

Authors:  Sarah Gutkind; Laura E Starbird; Sean M Murphy; Paul A Teixeira; Lauren K Gooden; Tim Matheson; Daniel J Feaster; Mamta K Jain; Carmen L Masson; David C Perlman; Carlos Del Rio; Lisa R Metsch; Bruce R Schackman
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.852

3.  PrEP Care Continuum Engagement Among Persons Who Inject Drugs: Rural and Urban Differences in Stigma and Social Infrastructure.

Authors:  Suzan M Walters; David Frank; Brent Van Ham; Jessica Jaiswal; Brandon Muncan; Valerie Earnshaw; John Schneider; Samuel R Friedman; Danielle C Ompad
Journal:  AIDS Behav       Date:  2021-10-09

4.  The Impact of the COVID-19 Pandemic on Drug Use Behaviors, Fentanyl Exposure, and Harm Reduction Service Support among People Who Use Drugs in Rural Settings.

Authors:  Rebecca S Bolinski; Suzan Walters; Elizabeth Salisbury-Afshar; Lawrence J Ouellet; Wiley D Jenkins; Ellen Almirol; Brent Van Ham; Scott Fletcher; Christian Johnson; John A Schneider; Danielle Ompad; Mai T Pho
Journal:  Int J Environ Res Public Health       Date:  2022-02-16       Impact factor: 3.390

5.  Structural and community changes during COVID-19 and their effects on overdose precursors among rural people who use drugs: a mixed-methods analysis.

Authors:  Suzan M Walters; Rebecca S Bolinski; Ellen Almirol; Stacy Grundy; Scott Fletcher; John Schneider; Samuel R Friedman; Lawrence J Ouellet; Danielle C Ompad; Wiley Jenkins; Mai T Pho
Journal:  Addict Sci Clin Pract       Date:  2022-04-25

6.  Supporting syringe services programs in the initiation and scale-up of vaccine administration: findings from in-depth interviews.

Authors:  Monique Carry; Danae Bixler; Mark K Weng; Mona Doshani; Emma Roberts; Martha P Montgomery
Journal:  Harm Reduct J       Date:  2022-09-01

7.  Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.

Authors:  Kiana Yazdani; Katerina Dolguikh; Wendy Zhang; Sara Shayegi-Nik; Jessica Ly; Shaughna Cooper; Jason Trigg; Sophia Bartlett; Rolando Barrios; Julio S G Montaner; Kate Salters
Journal:  PLoS One       Date:  2022-03-23       Impact factor: 3.240

8.  Considerations for the Design of Pre-exposure Prophylaxis (PrEP) Interventions for Women: Lessons Learned from the Implementation of a Novel PrEP Intervention.

Authors:  Suzan M Walters; Joey Platt; Amarachi Anakaraonye; Sarit A Golub; Chinazo O Cunningham; Brianna L Norton; Jae M Sevelius; Oni J Blackstock
Journal:  AIDS Behav       Date:  2021-06-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.